Calcifediol Treatment and COVID-19-Related Outcomes

Nogués, Xavier; Ovejero, Diana; Quesada‐Gómez, José Manuel; Bouillon, Roger; Arenas, Dolores; Pascual, Julio; Villar-García, Judith; Rial, Abora; Gimenez-Argente, Carme; Cos, ML; Rodriguez-Morera, Jaime; Campodarve, Isabel; Güerri‐Fernández, Robert; Pineda-Moncusí, Marta; García-Giralt, Natàlia

doi:10.2139/ssrn.3771318

Cited by 25 publications

(35 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These patients received 532 μg of oral 25(OH)D3 on first day of admission and 266 μg of oral 25(OH)D3 on days 3 and 7 of hospitalization, and then weekly until discharge or ICU admission ( 9 ). Similar to our study two retrospective cohort studies on patients admitted for COVID-19 ( 32 , 33 ) reported treatment with calcifediol reduced the risk of requirement for critical care by more than 80% and reduced the mortality risk by more than 70%”(32).…”

Section: Discussionsupporting

confidence: 87%

Treatment With 25-Hydroxyvitamin D3 (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-to-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With COVID-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial

Maghbooli

Sahraian

Jamalimoghadamsiahkali

et al. 2021

Endocrine Practice

View full text Add to dashboard Cite

Objective The goal of this randomized placebo-controlled clinical trial was to investigate the therapeutic efficacy of oral 25-hydroxyvitamin D 3 [25(OH)D 3 ] in improving vitamin D status in vitamin D deficient/insufficient patients infected with the SARS-CoV-2 (COVID-19) virus. Methods This is a multicenter randomized double blinded randomized placebo-controlled clinical trial. Participants were recruited from three hospitals that are affiliated to [Institution Blinded for Review], and [Institution Blinded for Review]. Results A total 106 hospitalized patients who had a circulating concentration of 25(OH)D <30 ng/ml were enrolled in this study. Within 30 and 60 days 79.4% (26 out of 34) and 100% (24 out of 24) of the patients who received 25(OH)D 3 became sufficient whereas ≤12.5% the patients in the placebo group became sufficient during 2 months follow-up. We observed an overall lower trend for hospitalization, ICU duration, needing ventilator assistance and mortality in the 25(OH)D3 group compared with placebo group but they weren’t statistically significant. Treatment with oral 25(OH)D 3 was associated with a significant increase in the lymphocyte percentage and decrease in the ratio of neutrophils to lymphocytes (NLR) in the patients. The lower NLR was significant associated with reduced ICU admission days and mortality. Conclusion Our analysis indicated that oral 25-hydroxyvitamin D 3 was able to correct vitamin D deficiency/insufficiency in COVID-19 patients that resulted in improved immune function by increasing blood lymphocyte percentage. RCTs with a larger sample size and with higher dose of 25(OH)D3 maybe needed to confirm the potential effect of 25(OH)D3 on reducing clinical outcomes in COVID-19 patients. Ethics and Dissemination The study protocol was approved by the Ethics Committee of [Institution Blinded for Review]. (Approval Number: IR.TUMS.VCR.REC.1399.061). Dissemination plans include academic publications, conference presentations and social media. Trial registration The protocol was registered with the Iranian Registry of Clinical Trials (IRCT) on April 11, 2020 [Number Blinded for Review]. and U.S. National Institutes of Health [Number Blinded for Review] on May 11, 2020.

show abstract

Section: Discussionsupporting

confidence: 87%

Treatment With 25-Hydroxyvitamin D3 (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-to-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With COVID-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial

Maghbooli

Sahraian

Jamalimoghadamsiahkali

et al. 2021

Endocrine Practice

View full text Add to dashboard Cite

show abstract

“…Vitamin D deficiency is more frequent in patients with obesity, asthma, and diabetes and therefore, among other factors, these pathologies lead to higher mortality in COVID-19. A recent prospective study of 930 patients showed that Vitamin D provided in the form of calcifediol during hospitalization reduces intensive care unit admission and mortality by more than 50% 4 . Considering that Vitamin D deficiency increases the cytokine storm and the risk of thrombosis in COVID-19 and that this supplement is safe (the risk of toxicity is extremely low at the usual doses), cheap, and well tolerated and is also useful for other pathologies, I believe it is worth using it at least during hospitalization for COVID-19, if not before.…”

Section: Rev Invest Clin (Ahead Of Print)mentioning

confidence: 99%

Coronavirus disease-19 Pandemic and Vitamin D: So Much for so Little?

Castro¹

2021

RIC

View full text Add to dashboard Cite

“…11 A controlled trial conducted in a COVID-19 ward in Spain showed a reduced mortality risk with an OR 0.21 [95% CI 0.10; 0.43] when calcifediol, 25(OH)D, the activated form of vitamin D was given on admission. 12 Jayawardena et al reported positive correlations for the prevalence of vitamin D deficiency with COVID-19 infections (r = 0.55; p = 0.01; R2 = 0.31) and mortalities (r = 0.50; p = 0.01; R2 = 0.25) in Asian countries. 13 A randomised control trial in India likewise concluded that individuals with adequate vitamin D levels turned SARS-CoV-2 RNA negative far earlier than the individuals who had vitamin D deficiency.…”

Section: Role Of Vitamin D Deficiency In Covid-19mentioning

confidence: 98%

Recommendations for High Vitamin D Supplementation to help Fight the COVID-19Pandemic and its Inclusion in National COVID-19 Management Guidelines

Kishore¹

2021

IJoYAH

View full text Add to dashboard Cite

Vitamin D in the human body is mainly synthesised in the skin on exposure to sunlight. Dietary sources like fish, fortified food, and supplements are highly variable exogenous sources but usually fail to source the required levels of vitamin D. Vitamin D levels are assessed by measuring circulating blood levels of the storage form produced by the liver, 25-hydroxyvitamin D [25(OH)D]. The optimal range of serum 25(OH)D level is 40-60 ng/ml. Diagnostic cut-offs for deficiency are < 20 ng/ml for depletion, 20-30 ng/ml for insufficiency, and > 30 ng/ ml for sufficiency, 4 but even higher levels are desirable especially for

show abstract

Calcifediol Treatment and COVID-19-Related Outcomes

Cited by 25 publications

References 36 publications

Treatment With 25-Hydroxyvitamin D3 (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-to-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With COVID-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial

Treatment With 25-Hydroxyvitamin D3 (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-to-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With COVID-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial

Coronavirus disease-19 Pandemic and Vitamin D: So Much for so Little?

Recommendations for High Vitamin D Supplementation to help Fight the COVID-19Pandemic and its Inclusion in National COVID-19 Management Guidelines

Contact Info

Product

Resources

About